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Inducibility of Paroxysmal Atrial Fibrillation. Background: Isoproterenol has been used to assess
inducibility during catheter ablation for paroxysmal PAF. However, no studies have determined the sensi-
tivity and specificity of isoproterenol for the induction of AF. It also is not clear whether isoproterenol is
equally effective in inducing AF in the clinical subtypes of vagotonic, adrenergic, and random AF.
Objective: To determine the sensitivity and specificity of isoproterenol for the induction of atrial fibrillation
(AF).
Methods: Isoproterenol was infused at 5, 10, 15, and 20 µg/min at 2-minute intervals or until AF was
induced in 20 control subjects with no history of AF and in 80 patients with PAF.
Results: Among the 20 control subjects, AF was induced by isoproterenol in one patient (5%). Among
the 80 patients with PAF, persistent AF was induced in 67 patients (84%, P < 0.001). Isoproterenol induced
AF in 15 of 17 patients (88%) with vagotonic AF, 11 of 11 patients (100%) with adrenergic AF, and 41 of 52
patients (79%) with random episodes of AF (P = 0.2). The yield of AF was 11% (9/80) after 5 µg/min, 28%
(22/80) after 10 µg/min, 51% (40/78) after 15 µg/min, and 88% (67/76) after 20 µg/min of isoproterenol
(P < 0.01). Isoproterenol had to be discontinued in four patients (5%) before reaching the maximum dose
due to reversible chest pain or systolic blood pressure <85 mmHg.
Conclusions: Isoproterenol at infusion rates up to 20 µg/min has a high sensitivity (88%) and specificity
(95%) for induction of AF in patients with PAF, regardless of whether the clinical subtype is vagotonic,
adrenergic, or random. (J Cardiovasc Electrophysiol, Vol. 19, pp. 466-470, May 2008.)
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Introduction
Several studies have used isoproterenol to assess for resid-
ual atrial fibrillation (AF) triggers after pulmonary vein iso-
lation in patients with paroxysmal AF.1-6 However, there has
been no systematic evaluation of the sensitivity and speci-
ficity of isoproterenol for the induction of AF prior to ra-
diofrequency ablation. It is recognized that paroxysmal AF
may be vagotonic in some patients and adrenergic or ran-
dom in others,7-11 but no prior studies have compared the in-
ducibility of AF by isoproterenol in these clinical subtypes.
The purpose of this study was to determine the sensitivity
and specificity of isoproterenol for the induction of AF and
to compare AF inducibility by isoproterenol between pa-
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The subjects of this study were 80 patients who underwent
radiofrequency catheter ablation of paroxysmal AF. There
were 59 men and 21 women, and their mean age was 58
± 11 years. The mean left atrial size and left ventricular
ejection fraction were 40 ± 5 mm (range: 29–51 mm) and
0.59 ± 0.07 (range: 0.45–0.80), respectively. AF had been
first diagnosed 7 ± 6 years prior to presentation. Among
the 80 subjects, hypertensive heart disease was present in
20 (25%), coronary artery disease in 5 (6%), a nonischemic
cardiomyopathy in 1, and a repaired atrial septal defect in 1.
Patients with coronary artery disease were excluded unless
there was documentation of a negative stress test. Patients
with hypertrophic obstructive cardiomyopathy or aortic or
mitral valve stenosis were excluded from the study, as were
patients who had been treated with amiodarone within the
prior 3 months.
The clinical subtype of paroxysmal AF was classified
based on a detailed clinical history as described previously.10
Episodes of AF that exclusively occurred nocturnally or post-
prandially were considered vagotonic, whereas episodes of
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AF that exclusively were triggered by exercise or adrenergic
stimulation were considered adrenergic. The remaining pa-
tients were considered to have random paroxysmal AF.7-9,11
A group of 20 otherwise healthy subjects with no history
of AF who underwent radiofrequency catheter ablation of
paroxysmal supraventricular tachycardia constituted a con-
trol group. The mean age of the control subjects was 46
± 17 years (P < 0.001, Mann-Whitney U test, compared
with patients with AF). There were 16 men and 4 women.
The mean left ventricular ejection fraction was 0.56 ±
0.06. Among these 20 patients, 14 had atrioventricular nodal
reentrant tachycardia, 4 had an accessory pathway, 1 had
atrial tachycardia, and 1 had no inducible supraventricular
tachycardia.
Electrophysiologic Study
All patients provided informed written consent prior to
the study. Electrophysiologic studies were performed in the
postabsorptive state. Antiarrhythmic drug therapy was dis-
continued at least 4–5 half-lives before the study. Conscious
sedation was achieved with fentanyl and midazolam. Vascular
access was obtained through a femoral vein. In patients under-
going an electrophysiologic study for treatment of supraven-
tricular tachycardia, quadripolar catheters were positioned in
the high right atrium, His bundle position and the right ven-
tricular apex. In patients with AF, catheter placement was as
previously described.1
Study Protocol
The study protocol was approved by the Institutional Re-
view Board. Only patients who presented in sinus rhythm
were included in the study. Isoproterenol was infused through
a femoral vein at rates of 5, 10, 15, and 20 µg/min for 2 min-
utes at each infusion rate. The isoproterenol infusion was dis-
continued upon induction of AF, a decrease in systolic blood
pressure to <85 mmHg, complaints of severe chest tightness,
electrocardiographic changes suggestive of ischemia, or upon
completion of the infusion protocol. Episodes of AF that oc-
curred during the first 10 minutes of isoproterenol washout
were considered to have been induced by isoproterenol.
In the control group, isoproterenol was infused upon com-
pletion of the clinically indicated portion of the electrophys-
iology procedure. AF and frequent atrial ectopy (bigeminy
or trigeminy) were considered to be a positive response to
isoproterenol.
Statistical Analysis
Continuous variables are expressed as mean ± 1 standard
deviation and were compared by Student’s t-test. Normality
of distribution was tested using Shapiro-Wilk’s test. Nonpara-
metric Mann-Whitney U test or Wilcoxon-matched pairs test
was used as appropriate when the distribution was not normal.
Categorical variables were compared by chi-square analysis
or with Fisher’s exact test where appropriate. A P value of
<0.05 indicated statistical significance.
Results
Effects of Isoproterenol in Control Subjects
Among the 20 control subjects, the mean baseline sinus
cycle length was 743 ± 134 ms and progressively decreased
Figure 1. Effect of isoproterenol dose on inducibility of AF. The cumulative
dose of isoproterenol that resulted in initiation of sustained AF in control
subjects or patients with PAF is shown. Because the isoproterenol infusion
was discontinued prematurely in four patients, only 78 and 76 of the 80
patients received isoproterenol at 15 µg/min and 20 µg/min, respectively.
to a mean of 399 ± 50 ms with infusion of isoproterenol up to
20 µg/min (P < 0.0001). AF was induced in one patient (5%)
and frequent premature atrial depolarizations were induced
in another patient (5%), in both cases during an infusion
rate of 20 µg/min (Fig. 1). AF persisted for >5 minutes and
transthoracic cardioversion was performed to restore sinus
rhythm.
Effects of Isoproterenol in Patients with Paroxysmal AF
Among the 80 patients with paroxysmal AF, the baseline
sinus cycle length progressively decreased from 892 ± 207
ms to 407 ± 121 ms after infusion of isoproterenol at 20
µg/min (P < 0.0001, Wilcoxon pairs test). There was not a
significant difference in the mean cycle length after infusion
of isoproterenol between the control subjects and the patients
with paroxysmal AF.
Among the 80 patients with paroxysmal AF, isoproterenol
induced persistent AF in 67 (84%) and frequent premature
atrial depolarizations or short bursts of AF in two (2%) pa-
tients (P < 0.0001, compared with control subjects, Fig. 1).
Persistent AF was induced by rapid atrial pacing in 8 of the
11 patients who did not have AF induced by isoproterenol.
The mean age of the patients with AF who did and did not
have inducible AF in response to isoproterenol was similar
(58 ± 10 years vs 56 ± 11 years, P = 0.54). AF was inducible
in a similar proportion of patients with AF who were younger
and older than 50 years (P = 1.0).
Among the 69 patients in whom isoproterenol induced
AF or frequent premature atrial depolarizations, AF persisted
beyond 30 minutes after discontinuation of isoproterenol in
67 (97%).
Dose-Response Relationship
Among the 80 patients with paroxysmal AF, the mean
maximum infusion rate of isoproterenol in the patients with
and without AF inducible by isoproterenol was 15 ± 5
µg/min and 17 ± 4 µg/min, respectively (P = 0.14).
Among the patients with paroxysmal AF, the cumulative
rates of inducibility were 11% (9 of 80) after 5 µg/min,
28% (22 of 80) after 10 µg/min, 51% (40 of 78) after
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TABLE 1
Diagnostic Accuracy of Isoproterenol for Induction of AF
Isoproterenol
Dose (µg/min) Sensitivity Specificity PPV NPV
5 11 100 100 22
10 28 100 100 26
15 51 100 100 66
20 88 95 99 73
Data shown are in %. PPV = positive predictive value; NPV = negative
predictive value.
15 µg/min, and 88% (67 of 76) after 20 µg/min (P < 0.01,
Fig. 1, Table 1).
Clinical Subtypes of Paroxysmal AF
Among the 80 subjects, 17 (21%) had vagotonic AF, 11
(14%) had adrenergic AF, and the remaining 52 (65%) had
random AF. AF was induced by isoproterenol in 15 of the 17
patients (88%) with vagotonic AF, in each of the 11 patients
with adrenergic AF (100%), and in 41 of the 52 patients
with random AF (79%, P = 0.2, Table 2). The mean dose of
isoproterenol required to induce AF was similar between the
patients with vagotonic (15 ± 6 µg/min), adrenergic (16 ±
5 µg/min) and random (15 ± 5 µg/min, P = 0.7) AF.
Diagnostic Accuracy
The sensitivity and specificity of isoproterenol for the in-
duction of AF were 88% and 95%, respectively. The positive
and negative predictive values were 99% and 73%, respec-
tively (Table 1). The overall diagnostic accuracy was 90%.
Adverse Effects
The isoproterenol infusion was discontinued prematurely
in 4 of the 80 patients (5%) because of chest discomfort in
two and a systolic blood pressure <85 mmHg in two patients
during infusion at rates of 10–15 µg/min. The symptoms and
hypotension quickly resolved after discontinuation of isopro-
terenol. There were no electrocardiogram changes suggestive
of ischemia in any of the patients.
Discussion
Main Findings
This study demonstrates that isoproterenol has a high sen-
sitivity and specificity for the induction of AF in patients
with paroxysmal AF. Induction of AF by isoproterenol is
TABLE 2
Diagnostic Accuracy of Isoproterenol at 20 µg/min for Induction of AF in
Patients with Vagotonic, Adrenergic, or Random AF
Clinical Subtype
of AF Sensitivity Specificity PPV NPV
Vagotonic AF 88 95 94 90
Adrenergic AF 100 95 92 100
Random AF 79 95 100 63
Data shown are in %. PPV = positive predictive value; NPV = negative
predictive value.
dose-dependent and requires infusion rates of 20 µg/min in
∼50% of the patients. Isoproterenol generally was well tol-
erated and the infusion was discontinued prematurely in only
5% of patients.
Despite differences in autonomic tone during spontaneous
initiation of AF in the three clinical subtypes of paroxysmal
AF, isoproterenol induced AF in a similar proportion of pa-
tients with vagotonic, adrenergic, and random episodes of
AF.
Isoproterenol, Inducibility, and Mode of Onset of AF
The mechanism by which isoproterenol induces sustained
AF may be multifactorial. Isoproterenol decreases the si-
nus cycle length, shortens the refractory period in the PVs
and atrium, facilitates calcium release from the sarcoplasmic
reticulum, and promotes early after-depolarizations.6,12,13 An
experimental study demonstrated that isoproterenol results in
a rise of intracellular calcium concentrations prior to the ini-
tiation of focal PV discharges, leading to phase singularities
at the PV-left atrium junction due to anisotropic reentry.14
Isoproterenol may facilitate automaticity and triggered ac-
tivity.15 A clinical observation has been the suppression of
premature depolarizations and bursts of AF with propranolol
and verapamil in patients with paroxysmal AF, suggesting
that both automaticity and triggered activity may play a role
in mediating proarrhythmic effects of isoproterenol.2,16 In
another study, dissociated rhythms in PVs after isolation had
a similar response to isoproterenol as the sinus node, sug-
gesting automaticity as a potential mechanism.17
In patients with adrenergic AF, adrenergic stimulation by
isoproterenol would be expected to induce AF. However, it is
not intuitively obvious that isoproterenol would induce AF in
a large proportion of patients with vagotonic AF. A possible
mechanism by which isoproterenol may facilitate the initia-
tion of AF in patients with vagotonic AF may be accentuated
antagonism.18-22 Stimulation of ganglionated plexi and an
increase in parasympathetic tone have been demonstrated to
facilitate the initiation and perpetuation of AF by shorten-
ing the effective refractory period and promoting triggered
activity and spontaneous depolarizations.23-25 It is possible
that the increase in parasympathetic tone that occurs during
infusion of isoproterenol promotes AF in these patients.
Initiation of AF may primarily depend on the instan-
taneous balance between sympathetic and parasympathetic
tone. During spontaneous episodes of vagotonic AF, the ef-
fects of an increase in parasympathetic tone may be clinically
more apparent. On the other hand, infusion of high-dose iso-
proterenol may lead to a marked increase in parasympathetic
effects through accentuated antagonism. However, these in-
creased parasympathetic effects may not be clinically mani-
fest due to prevailing adrenergic stimulation. It also is possi-
ble that the parameters often used to assess vagal tone, such
as changes in sinus cycle length, may not have sufficient ac-
curacy to detect instantaneous changes in parasympathetic
tone.
In a prior experimental study, pretreatment with at-
ropine abolished the inducibility of AF by isoproterenol
in open-chest dogs.26 Pretreatment with a beta-blocker did
not have a similar effect, but led to an increase in the
concentration of acetylcholine necessary to induce AF.
On the other hand, coadministration of isoproterenol de-
creased the acetylcholine concentration needed to induce
Oral et al. Inducibility of Paroxysmal Atrial Fibrillation 469
AF. These observations suggest that parasympathetic activa-
tion is necessary for induction of AF and that isoproterenol
may have a synergistic or facilitatory role. Isoproterenol may
facilitate triggered activity due to an increase in intracellu-
lar calcium concentration, whereas shortening of the action
potential duration and effective refractory period by parasym-
pathetic activation may further promote spontaneous depo-
larizations and the perpetuation of AF. Adrenergic neurons
also appear to be prevalent in the ganglionated plexi often
located in the venoatrial junction.24
Another finding of this study is that AF induced by iso-
proterenol usually persisted beyond the point of complete
isoproterenol washout. This indicates that once AF was trig-
gered, self-perpetuating mechanisms, such as intermittent
pulmonary vein tachycardias,27 were activated.
Limitations
A limitation of this study is that the effects of isoproterenol
were examined in patients who underwent an electrophysio-
logic study under conscious sedation. It is not clear whether
isoproterenol would have similar effects if administered to
patients under general anesthesia.
It may be argued that the depth of sedation may not have
been the same between the control and AF groups. However,
sedation was kept to a minimum in both groups, and the
changes in sinus cycle length in response to isoproterenol
were similar in both groups.
The findings are applicable only to patients with paroxys-
mal AF. It remains to be determined if isoproterenol would
also exert similar effects in patients with chronic AF.
Another limitation may be that patients in the control
group with no history of AF were younger than patients with
AF. However, the mean age of the patients with AF who did
and did not have inducible AF in response to isoproterenol
was similar; and AF was inducible in a similar proportion of
patients with AF who were younger and older than 50 years.
Therefore, it is unlikely that age had a significant effect on
inducibility of AF.
Clinical subtypes of AF were determined based on pa-
tient’s history. However, continuous electrocardiographic
monitoring for extended period of time to capture the ini-
tiation of AF would not have been feasible.
Finally, because the effects of isoproterenol may be time-
dependent, it is possible that AF may have been induced at
lower infusion rates if more time was allowed before increas-
ing the infusion rate.
Clinical Implications
Isoproterenol has been used in prior studies to assess the
inducibility of AF after ablation at widely divergent infusion
rates of 2–20 µg/min.1-4 The findings of this study demon-
strate that an isoproterenol infusion of 20 µg/min is necessary
to induce AF in >50% of the patients. This high infusion rate
rarely induces AF in patients without a history of AF and
generally is tolerated.
Because isoproterenol may not induce AF in ∼15% of
patients with paroxysmal AF even at an infusion rate of
20 µg/min, it is important to assess the inducibility of AF
before ablation if noninducibility of AF is to be used as an
endpoint of the ablation strategy.
Infusion of high-dose isoproterenol to assess inducibil-
ity of AF may also be considered in patients who undergo
an electrophysiologic study to determine the mechanisms of
their palpitations and/or syncope after having undergone a
negative noninvasive workup.
Finally, the prognostic significance of reassessment of in-
ducibility of AF using isoproterenol with and without rapid
atrial pacing after ablation for AF remains to be determined
in future studies.
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